2022
Immunotherapy After Chemotherapy and Radiation for Clinical Stage III Lung Cancer
Pichert MD, Canavan ME, Maduka RC, Li AX, Ermer T, Zhan PL, Kaminski M, Udelsman BV, Blasberg JD, Park HS, Goldberg SB, Boffa DJ. Immunotherapy After Chemotherapy and Radiation for Clinical Stage III Lung Cancer. JAMA Network Open 2022, 5: e2224478. PMID: 35925606, PMCID: PMC9353596, DOI: 10.1001/jamanetworkopen.2022.24478.Peer-Reviewed Original ResearchConceptsStage III non-small cell lung cancerNon-small cell lung cancerClinical stage III non-small cell lung cancerUnresectable stage III non-small cell lung cancerPropensity-matched sampleGeneral US populationSurvival advantageCohort studyLung cancerMultivariable Cox proportional hazards modelsUS populationStage III lung cancerMedian age 66 yearsCox proportional hazards modelNational Cancer DatabaseEfficacy of immunotherapyAge 66 yearsProtocol rangesCell lung cancerClinical trial populationsProportional hazards modelTerms of ageImmunotherapy initiationImmunotherapy recipientsImmunotherapy use
2021
Optimal Radiation Dose for Stage III Lung Cancer—Should “Definitive” Radiation Doses Be Used in the Preoperative Setting?
Saffarzadeh AG, Canavan M, Resio BJ, Walters SL, Flores KM, Decker RH, Boffa DJ. Optimal Radiation Dose for Stage III Lung Cancer—Should “Definitive” Radiation Doses Be Used in the Preoperative Setting? JTO Clinical And Research Reports 2021, 2: 100201. PMID: 34590044, PMCID: PMC8474436, DOI: 10.1016/j.jtocrr.2021.100201.Peer-Reviewed Original ResearchLong-term mortality riskStage III NSCLCLow dosePreoperative settingMortality riskHigh doseRadiation doseClinical stage III patientsNational Cancer Database dataStage III lung cancerStage III patientsUse of surgeryLength of stayGy of radiationCox proportional hazardsComparative effectiveness analysisOptimal radiation doseSingle-dose strategyLong-term survivalRadiation dosesLogistic regression modelsDefinitive chemoradiotherapyN2 patientsNonsurgical patientsPerioperative outcomes